Independent directory Public ClinicalTrials.gov records United States
Condition Directory

Multiple Myeloma clinical trials

Directory of U.S. ClinicalTrials.gov public records for Multiple Myeloma. Browse Multiple Myeloma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 8, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
2319
Shown on this page
12
Current sort
Recently updated
Condition scope
Multiple Myeloma
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Multiple Myeloma studies are organized in the registry

Myeloma listings distinguish newly diagnosed from relapsed/refractory disease in their titles, and precursor conditions — smoldering myeloma and MGUS — are usually registered as separate condition terms. Cell-based and antibody platforms (CAR-T, bispecific antibodies) appear by name in many current titles.

Terms that often appear in related listings

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Multiple Myeloma. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1189–1200 of 2,319 matching trials for Multiple Myeloma.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Conditions
Multiple Myeloma
Interventions
myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D
Device · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Terminated Phase 1Phase 2 Interventional Results available

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

NCT02757326
Conditions
Multiple Myeloma
Interventions
Opaganib
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Multiple Myeloma
Interventions
Bortezomib, Granulocyte colony-stimulating factor (G-CSF), Mozobil
Drug
Lead sponsor
Siddhartha Ganguly
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Westwood, Kansas
Terminated Phase 1Phase 2 Interventional Results available

Tinostamustine Conditioning and Autologous Stem Cell

NCT03687125
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma With Failed Remission
Interventions
Tinostamustine, Autologous Stem Cell Transplant (ASCT)
Drug · Procedure
Lead sponsor
Mundipharma-EDO GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • Kansas City, Kansas • New York, New York + 4 more
Conditions
Recurrent Plasma Cell Myeloma
Interventions
Dexamethasone, HDAC Inhibitor AR-42, Laboratory Biomarker Analysis, Pomalidomide
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Completed Not applicable Interventional Results available

Unrelated Umbilical Cord Blood (UBC)Transplantation

NCT01768845
Conditions
Chronic Myelogenous Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Severe Aplastic Anemia
Interventions
umbilical cord blood (UCB)
Genetic
Lead sponsor
West Virginia University
Other
Eligibility
16 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Myeloid Leukemia, Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Myeloproliferative Disorders
Interventions
Donor lymphocyte preparation depleted of host functional alloreactive T-cells
Biological
Lead sponsor
Kiadis Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Multiple Myeloma
Interventions
Ixazomib
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Multiple Myeloma
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hematologic Malignancies
Interventions
Romiplostim
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Multiple Myeloma
Interventions
Propranolol
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Multiple Myeloma
Interventions
Pack Health's digital life coaching (DLC)
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California

About this Multiple Myeloma clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Multiple Myeloma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Multiple Myeloma.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Multiple Myeloma.